{
    "nct_id": "NCT03314935",
    "official_title": "A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors",
    "inclusion_criteria": "* Histologically or cytologically confirmed diagnosis of selected advanced or metastatic solid tumors.\n* Presence of measurable disease per RECIST v1.1.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n* Baseline archival tumor specimen available or willingness to undergo a pretreatment tumor biopsy to obtain the specimen.\n* Resolution of treatment-related toxicities.\n* Adequate hepatic, renal, cardiac, and hematologic function.\n* Additional cohort-specific criteria may apply.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Subjects who participated in any other study in which receipt of an investigational study drug or device occurred within 28 days or 5 half-lives (whichever is longer) prior to first dose.\n* Has received a prior monoclonal antibody within 4 weeks or 5 half-lives (whichever is shorter) before administration of study drug.\n* Has had prior chemotherapy or targeted small molecule therapy within 2 weeks before administration of study treatment.\n* Has received prior approved radiotherapy within 14 days of study therapy.\n* Has had known additional malignancy that is progressing or requires active treatment, or history of other malignancy within 2 years of study entry.\n* Has an active autoimmune disease that has required systemic treatment in past 2 years.\n* Has an active infection requiring systemic therapy.\n* Has known active CNS metastases and/or carcinomatous meningitis.\n* Women who are pregnant or breastfeeding.",
    "miscellaneous_criteria": ""
}